Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) EBIT Margin: 2020-2025

Historic EBIT Margin for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to 48.67%.

  • Apellis Pharmaceuticals' EBIT Margin rose 7269.00% to 48.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.91%, marking a year-over-year increase of 3914.00%. This contributed to the annual value of -21.11% for FY2024, which is 10928.00% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported EBIT Margin of 48.67% as of Q3 2025, which was up 360.98% from -18.65% recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' EBIT Margin registered a high of 2,984.22% during Q1 2021, and its lowest value of -31,185.71% during Q2 2021.
  • Over the past 3 years, Apellis Pharmaceuticals' median EBIT Margin value was -36.03% (recorded in 2024), while the average stood at -73.29%.
  • Per our database at Business Quant, Apellis Pharmaceuticals' EBIT Margin plummeted by 3,285,756bps in 2021 and then soared by 3,027,514bps in 2022.
  • Quarterly analysis of 5 years shows Apellis Pharmaceuticals' EBIT Margin stood at -148.29% in 2021, then crashed by 57,559bps to -723.88% in 2022, then skyrocketed by 66,614bps to -57.74% in 2023, then soared by 4,543bps to -12.31% in 2024, then surged by 7,269bps to 48.67% in 2025.
  • Its EBIT Margin was 48.67% in Q3 2025, compared to -18.65% in Q2 2025 and -49.96% in Q1 2025.